ArticleApplied intelligence (Dordrecht, Netherlands)2021
The analysis of isolation measures for epidemic control of COVID-19.
Article in Applied intelligence (Dordrecht, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Efficient and assured reinforcement learning-based building HVAC control with heterogeneous expert-guided training.Scientific reports · 2025Article
- Modelling spatial variations of novel coronavirus disease (COVID-19): evidence from a global perspective.GeoJournal · 2022Article
- Cross-sectional analysis and data-driven forecasting of confirmed COVID-19 cases.Applied intelligence (Dordrecht, Netherlands) · 2022Article
- Optimal control analysis of COVID-19 vaccine epidemic model: a case study.European physical journal plus · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper proposes a susceptible exposed infectious recovered model (SEIR) with isolation measures to evaluate the COVID-19 epidemic based on the prevention and control policy implemented by the Chinese government on February 23, 2020. According to the Chinese government's immediate isolation and centralized diagnosis of confirmed cases, and the adoption of epidemic tracking measures on patients to prevent further spread of the epidemic, we divide the population into susceptible, exposed, infectious, quarantine, confirmed and recovered. This paper proposes an SEIR model with isolation measures that simultaneously investigates the infectivity of the incubation period, reflects prevention and control measures and calculates the basic reproduction number of the model. According to the data released by the National Health Commission of the People's Republic of China, we estimated the parameters of the model and compared the simulation results of the model with actual data. We have considered the trend of the epidemic under different incubation periods of infectious capacity. When the incubation period is not contagious, the peak number of confirmed in the model is 33,870; and when the infectious capacity is 0.1 times the infectious capacity in the infectious period, the peak number of confirmed in the model is 57,950; when the infectious capacity is doubled, the peak number of confirmed will reach 109,300. Moreover, by changing the contact rate in the model, we found that as the intensity of prevention and control measures increase, the peak of the epidemic will come earlier, and the peak number of confirmed will also be significantly reduced. Under extremely strict prevention and control measures, the peak number of confirmed cases has dropped by nearly 50%. In addition, we use the EEMD method to decompose the time series data of the epidemic, and then combine the LSTM model to predict the trend of the epidemic. Compared with the method of directly using LSTM for prediction, more detailed information can be obtained.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.